

Haematologica
HAEMATOL/2018/209692
Version 3

Differential effects of therapeutic complement Inhibitors on serum bactericidal activity against nongroupable meningococcal isolates recovered from patients treated with eculizumab

Dan M. Granoff, Howard Kim, Nadav Topaz, Jessica MacNeil, Xin Wang, and Lucy A. McNamara

Disclosures: This investigation was supported by research grants R01 AI046464 and R01 AI114701 from the National Institute of Allergy and Infectious Diseases, NIH. Achillion Pharmaceutical, Inc., provided ACH-4471. Drs. Mingjun Huang, Steven Podos and Manuel Galvan, Achillion Pharmaceutical, Inc., New Haven CT, and Sanjay Ram, University of Massachusetts Medical School, Worcester, MA, provided critical review of the manuscript. No funding was provided by Achillion Pharmaceutical, Inc; The authors were solely responsible for the investigation, design, data analysis and writing of the manuscript other than critical review described above. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Conflict of interest. DMG is an inventor on patent applications or on issued patents in the area of meningococcal vaccines. Rights to these inventions have been assigned to UCSF Benioff Children's Hospital Oakland. These patents do not involve the subject of the manuscript under consideration. HK, NT, JM, XW, and LAM declare they have no conflicts of interest.

Contributions: DMG and LAM designed the study, performed data analysis and wrote the manuscript HK and NT performed research and data analysis. JMN and XW supervised the study and and participated in writing the manuscript